CAR T cell therapies for diffuse midline glioma.
Trends Cancer
; 9(10): 791-804, 2023 10.
Article
em En
| MEDLINE
| ID: mdl-37541803
ABSTRACT
Diffuse midline glioma (DMG) is a fatal pediatric cancer of the central nervous system (CNS). The location and infiltrative nature of DMG prevents surgical resection and the benefits of palliative radiotherapy are temporary; median overall survival (OS) is 9-11 months. The tumor immune microenvironment (TIME) is 'cold', and has a dominant immunosuppressive myeloid compartment with low levels of infiltrating lymphocytes and proinflammatory molecules. Because survival statistics have been stagnant for many decades, and therapies targeting the unique biology of DMG are urgently needed, this has prompted the clinical assessment of chimeric antigen receptor (CAR) T cell therapies in this setting. We highlight the current landscape of CAR T cell therapy for DMG, the role the TIME may play in the response, and strategies to overcome treatment obstacles.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Imunoterapia Adotiva
/
Glioma
Limite:
Child
/
Humans
Idioma:
En
Revista:
Trends Cancer
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Austrália